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Abstract
Background: Angiopoietin-1 (Ang-1) and -2 (Ang-2) are keyplayers in the regulation of endothelial homeostasis
and vascular proliferation. Angiopoietins may play an important role in the pathophysiology of cerebral vasospasm
(CVS). Ang-1 and Ang-2 have not been investigated in this regard so far.
Methods: 20 patients with subarachnoid hemorrhage (SAH) and 20 healthy controls (HC) were included in this
prospective study. Blood samples were collected from days 1 to 7 and every other day thereafter. Ang-1 and Ang-
2 were measured in serum samples using commercially available enzyme-linked immunosorbent assay. Transcranial
Doppler sonography was performed to monitor the occurrence of cerebral vasospasm.
Results: SAH patients showed a significant drop of Ang-1 levels on day 2 and 3 post SAH compared to baseline
and HC. Patients, who developed Doppler sonographic CVS, showed significantly lower levels of Ang-1 with a
sustained decrease in contrast to patients without Doppler sonographic CVS, whose Ang-1 levels recovered in the
later course of the disease. In patients developing cerebral ischemia attributable to vasospasm significantly lower
Ang-1 levels have already been observed on the day of admission. Differences of Ang-2 between SAH patients and
HC or patients with and without Doppler sonographic CVS were not statistically significant.
Conclusions: Ang-1, but not Ang-2, is significantly altered in patients suffering from SAH and especially in those
experiencing CVS and cerebral ischemia. The loss of vascular integrity, regulated by Ang-1, might be in part
responsible for the development of cerebral vasospasm and subsequent cerebral ischemia.
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Background
Subarachnoid hemorrhage (SAH) accounts for 2-5% of
all new strokes and is still associated with high morbid-
ity and mortality [1,2]. In about 85% of all patients,
non-traumatic SAH is caused by the rupture of an intra-
cranial aneurysm [3]. Cerebral vasospasm (CVS) is one
of the most important complications of SAH and may
be associated with delayed cerebral ischemia (DCI) fre-
quently resulting in poor functional outcome and death
[4-6]. Various mechanisms are discussed to be involved
in the pathophysiology of CVS. Apart from smooth
muscle contraction and an increase of spasmogens such
as oxyhemoglobin or bilirubin oxidation products an
imbalance of endothelium-derived vasoconstrictor and
vasodilator substances is thought to play a crucial role
in CVS pathogenesis [7,8].
Angiopoietin-1 (Ang-1) and -2 (Ang-2) are two antag-
onistic ligands on the endothelial Tie-2 receptor regulat-
ing vascular homeostasis and endothelial stability [9,10].
Ang-1 is constitutively expressed by perivascular cells
such as smooth muscle cells, fibroblasts, pericytes, plate-
lets or neutrophils [9]. Constitutive Ang-1/Tie-2 signal-
ing is important for endothelial cell survival and the
maintenance of vascular integrity [11]. Ang-1 mediates
anti-inflammatory and anti-adhesive properties on the
vascular endothelium and promotes interendothelial
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any medium, provided the original work is properly cited.cell-cell stability directly antagonizing hyperpermeability
mediated by vascular endothelial growth factor [12-14].
Ang-2 is almost exclusively expressed by endothelial
cells and released upon endothelial activation [15]. Ang-
2 has proapoptotic and proinflammatory effects on
endothelial cells, promotes the expression of adhesion
molecules facilitating leukocyte migration and induces
vascular leakage [16,17].
High serum levels of Ang-2 together with a decrease
of the protective factor Ang-1 are associated with poor
outcome and death in acute lung injury, severe sepsis,
cerebral malaria and various other diseases [18-24]. In a
recent publication by our group, we showed that
endothelial microparticles are elevated in patients with
CVS and DCI indicating an important role of the
endothelium in CVS pathophysiology [25]. The current
study investigates other factors involved in vascular
homeostasis.
The primary hypothesis was that the angiopoietin sys-
tem is altered in patients developing severe vasospasm
and radiographic infarcts after SAH. Therefore, Ang-1
and Ang-2 serum concentrations were longitudinally
measured in SAH patients monitored for the occurrence
of CVS and DCI.
Methods
Study Population
Between November 2007 and January 2009 twenty con-
secutive patients with aneurysmal SAH admitted to the
neurocritical care unit of the Department of Neurology
of Innsbruck Medical University were enrolled in this
prospective study. All patients were treated by endovas-
cular coiling with electrolytically detachable platinum
coils, six patients (30%) received additional vascular
stents. The study protocol was approved by the Ethics
Committee of Innsbruck Medical University (Reference
Number UN3021, 256/4.17). Inclusion criteria: SAH
confirmed by cerebral computed tomography (CT), rup-
tured intracranial aneurysm demonstrated by digital
subtraction angiography (DSA) for which interventional
coiling was possible, first signs and symptoms having
occurred within 48 hours before screening, written
informed consent before recruitment or at time of
regaining consciousness and WFNS grades I-V. Exclu-
sion criteria: intracerebral or intraventricular blood
without aneurysmal bleeding source, moderate to severe
vasospasm at screening angiography, known coagulopa-
thies, treatment with thrombocyte aggregation inhibitors
or vitamin-K antagonists and severe pre-existing conco-
mitant diseases.
Twenty age and gender matched healthy volunteers
were recruited from hospital workers and relatives of
the study investigators (mean age: 52.2, range: 33-68).
All data was analyzed on an intention-to-treat basis.
Sample collection and measurement
Blood samples of SAH patients were prospectively col-
lected daily for the first 7 days, then every other day
until 15 days post SAH. The first sample was taken
before DSA was performed. Single blood samples from
20 age and gender matched volunteer donors served as
healthy controls. Blood was collected using Sarstedt
Monovette serum tubes. After at least 30 minutes of
clotting time serum was obtained by centrifugation at
1500 rcf for 15 min within two hours after blood collec-
tion and stored at -80°C until use. Ang-1 and Ang-2
were measured in serum samples using enzyme-linked
immunosorbent assay (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions.
Transcranial Doppler sonography (TCD) and patient
management
TCD was performed daily from day 1 to 7 and every
other day thereafter. Recordings of the mean blood flow
velocities (mBFV) were performed through the trans-
temporal ultrasound window using a 2-MHz handheld
transducer probe (Compumedics DWL Multidop X4,
Melbourne, Australia) when pCO2 levels where within
normal ranges. Doppler sonographic cerebral vasospasm
(dCVS) was defined as mBFV of 120 cm/s or more in
the middle cerebral artery [26]. DCI was defined as new
infarct on CT scan that had not been detected on the
admission or the immediate post-interventional scan,
and that was classified as vasospasm related by the
research team. Other potential causes of CT pathologies,
(e.g. rebleeding, cerebral edema or ventriculitis) were
excluded. CT scans were also performed at discharge
and were assessed by an independent radiologist.
At the end of hospitalization and after 6 months out-
come was evaluated by modified Rankin Scale (mRS)
and the Glasgow Outcome Scale (GOS). Demographic,
clinical and laboratory values were recorded prospec-
tively throughout the study. Patients experiencing dCVS
received hemodynamic augmentation involving a target
central venous pressure of > 8 mm Hg according to
local protocols, which have been published previously
[2]. Hypertension was induced using norepinephrine or
phenylephrine infusion and fluid to maintain a mean
arterial blood pressure of ≥100 mmHg. All patients
received nimodipine either per os or intravenously at a
daily dose of 300 mg, unless hemodynamic instability or
hypotension occurred.
Statistical methods
Angiopoietin levels were compared between the patient
groups by Wilcoxon rank-sum test or Wilcoxon signed-
rank test, as appropriate. The false discovery rate (FDR)
criterion was used for controlling the errors in multiple
comparisons [27]. To test the association between
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important covariates (age, sex, white blood cell count
(WBC), C-reactive protein (CRP) and body tempera-
ture), generalized estimation equations (GEE) were cal-
culated with day post SAH and presence of dCVS as
factors. To avoid co-linearity five different models were
calculated, one for each of the respective covariates.
Ang-1 and Ang-2 values were transformed logarithmi-
cally for this approach. Data are presented as mean ±
SEM unless otherwise stated. Calculations were done
using the PASW 18 (SPSS Inc., Chicago, IL, USA).
Graphs were drawn with GraphPad Prism 5.00 software
(GraphPad Prism Software Inc., San Diego, CA, USA).
Results
Patients’ characteristics
Patients’ age ranged from 31 to 66 years (mean 52.2
years), 4 patients were of male gender, 16 were female.
One patient showed mild vasospasm during intervention
on day one. Another ten patients developed dCVS
between day 2 and 13 (1 patient on day 2, 4 patients on
day 4, 3 patients on day 6, 1 patient on day 11 and 1
patient on day 13). Seven patients developed cerebral
ischemia attributable to vasospasm (CIV). Demographic,
clinical and laboratory characteristics of all patients are
listed in table 1 and were compared based on the pre-
sence of dCVS. Baseline characteristics were comparable
between both groups.
Time course of Ang-1 and Ang-2 serum levels
Ang-1 levels decreased significantly on day 2 and 3
compared to baseline (p < 0.05, figure 1a). Ang-1 levels
on days 2 and 3 also differed significantly between SAH
patients and healthy controls (p < 0.05). Compared to
day 2, when Ang-1 levels reached lowest values, there
was a significant increase starting on day 5 reaching
levels comparable to healthy controls (p < 0.05 for days
5 and 7, p < 0.01 for days 9, 11, 13 and 15).
Ang-2 levels did not differ significantly between days
(figure 1b) or between patients and healthy controls.
There was a trend towards higher Ang-2 serum concen-
trations in SAH patients on day 1 compared to healthy
controls (p = 0.063).
Ang-2 levels were significantly higher in patients with
Fisher grade 4 compared to patients with Fisher grade 2
and 3 (p < 0.01, figure 2). Neither Ang-1 nor Ang-2
levels differed significantly between patients receiving
additional vascular stents and patients without stents
(data not shown).
Doppler sonographic cerebral vasospasm
To analyze the time course of angiopoietin levels and its
association to the development of dCVS, multivariate
generalized estimation equations were applied with day
post SAH and presence of dCVS as factors including
important covariates (age, sex, WBC, CRP and body
temperature). These models showed a statistically highly
significant effect of the interaction of both factors indi-
cating different dynamics for Ang-1 in patients with
or without dCVS, respectively (p < 0.001, figure 3). In
contrast to patients without dCVS, in whom Ang-1
increased earlier starting from day 3, patients suffering
from dCVS showed a delayed increase of Ang-1 serum
concentrations.
For Ang-2 serum levels no significant association to
dCVS was found (data not shown).
Cerebral ischemia attributable to vasospasm
Ang-1 serum levels on day 1 were significantly lower in
patients who developed CIV (n = 7) compared to patients
without CIV in the later course of SAH (n = 13)
Table 1 Baseline characteristics including demographic
and laboratory data of the study population
Parameter dCVS
absent
dCVS
present
p-
value
number of patients 91 1
age (mean, range) 52.6 (31-
66)
51.9 (39-64) 0.655*
female gender, n (%) 8 (88.9%) 8 (72.7%) 0.369†
WFNS scale, n (%) 0.119†
I 4 (44.4%) 3 (27.3%)
II 0 (0%) 4 (36.4%)
III 2 (22.2%) 0 (0%)
IV 1 (11.1%) 3 (27.3%)
V 2 (22.2%) 1 (9.1%)
Fisher grade, n (%) 0.243†
II 2 (22.2%) 0 (0%)
III 2 (22.2%) 4 (36.4%)
IV 5 (55.6%) 7 (63.6%)
mRS on discharge 0.545†
0 3 (33.3%) 4 (36.4%)
1 3 (33.3%) 1 (9.1%)
2 0 (0%) 1 (9.1%)
3 1 (11.1%) 3 (27.3%)
4 0 (0%) 1 (9.1%)
5 1 (11.1%) 0 (0%)
6 1 (11.1%) 1 (9.1%)
Length of stay in days, mean
(range)
20.3 (9-41) 25.5 (12-53) 0.394*
Occlusive hydrocephalus
requiring EVD
3 (33.3%) 7 (63.6%) 0.178†
Ventriculo-peritoneal shunt 1 (11.1%) 1 (9.1%) 0.881†
Intracerebral hemorrhage 3 (33.3%) 3 (27.3%) 0.769†
Cerebral edema 5 (55.6%) 8 (72.7%) 0.423†
dCVS: Doppler sonographic cerebral vasospasm, WFNS: World federation of
neurosurgical societies, mRS: modified Rankin scale, EVD: external ventricular
drainage, Ang-1: angiopoietin-1, Ang-2: angiopoietin-2. * Analysis of variance,
† chi-square test.
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could verify a time dependent difference of Ang-1 in
patients with and without CIV showing a highly signifi-
cant effect of the interaction of factors CIV and day post
SAH, independent of the above mentioned covariates
(p < 0.001; figure 4).
For Ang-2 serum levels no significant association to
CIV could be found (data not shown).
Discussion
This pilot study describes the time course of Ang-1 and
Ang-2 serum levels in patients with aneurysmal SAH
and their association with the development of dCVS and
CIV. Our main findings were: 1) Ang-1 serum concen-
trations were significantly lower in SAH patients on
days 2 and 3 compared to baseline levels, 2) serum
levels of Ang-1 differed significantly between SAH
patients and healthy controls, 3) patients with dCVS,
and in particular patients with CIV secondary to dCVS,
revealed a different time course of Ang-1 serum concen-
trations with delayed recovery of low Ang-1 levels
observed in the early course of the disease.
The vascular endothelium modulates vascular tone
through the release of various vasoactive substances reg-
ulating smooth muscle cell contraction [28]. A sensitive
equilibrium between vasoconstricting and vasorelaxing
substances is crucial for the maintenance of normal
(blood) vessel diameter [28]. CVS is characterized by a
prolonged and enhanced contraction of smooth muscle
cells in the arterial vessel wall [28]. Amongst others it is
caused by calcium-dependent vasoconstriction, upregu-
lation of vasoconstrictors and decreased levels of vasore-
laxing substances such as Endothelin-1 (ET-1) and nitric
oxide (NO), respectively [28]. ET-1 is the most impor-
tant endothelial factor mediating vasoconstriction and is
up-regulated during CVS [29]. Interestingly, Ang-1
down-regulates the expression of ET-1 in vitro reducing
ET-1 mRNA and protein levels [30]. Results from ani-
mal experiments show reduced ET-1 after injection of
Ang-1 transfected fibroblast cells in the rat lung [30].
Moreover, it was shown that Ang-1 up-regulates the
endothelial nitric oxide synthase, an important source of
vasorelaxant NO. In our study, Patients with dCVS, and
in particular with CIV, revealed a delayed increase of
Ang-1 and showed lower values of Ang-1. It is tempting
to speculate that a lack of Ang-1 contributes to outba-
lanced vasoconstrictive substances such as ET-1.
Another important feature of CVS is endothelial cell
apoptosis [31,32]. Cerebral endothelial cell death has
been reported after SAH in rats [33]. Apoptosis of
endothelial cells has been suggested to expose smooth
muscle cells within the vessel walls to damaging and
vasoconstrictive substances within the blood flow [32].
Figure 1 (A) Angiopoietin-1 (Ang-1, ng/ml) and (B) angiopoietin-
2 (Ang-2, ng/ml) serum concentrations in patients with
aneurysmal subarachnoid hemorrhage (white boxes) and
healthy control subjects (grey box). Wilcoxon rank-sum test for
comparisons of HC with SAH patients, Wilcoxon signed-rank test for
comparisons of the respective days among SAH patients. P-values
adjusted for multiple comparisons by the FDR-method. **, p < 0.01.
Figure 2 Angiopoietin-2 (Ang-2, ng/ml) serum levels in
patients with Fisher grade 2 and 3 compared to Fisher grade
4. Mean and SEM. Wilcoxon rank-sum test. **, p < 0.01.
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function of angiopoietins with Ang-1 ensuring endothe-
lial survival and Ang-2 inducing endothelial cell death
[9,10]. We found decreased levels of Ang-1, an anti-
apoptotic factor on endothelial cells, in patients with
dCVS. This could further support the importance of
endothelial apoptosis in the pathogenesis of CVS after
SAH.
O t h e rm a r k e r sf o rv a s c u l a ri n j u r ya r ee n d o t h e l i a l
microparcticles, which have been recently found to be
associated with dCVS and CIV by our study group [25].
Ang-1 has been shown to suppress the generation of
endothelial microparticles in vitro [34]. Lower Ang-1
levels might explain the increased levels of endothelial
microparticles observed in patients with dCVS and CIV.
Data from various experimental and clinical studies
suggest that Ang-1 is protective in cerebral ischemia. In
the acute phase after ischemic stroke, Ang-1 is regarded
as a protective factor on the vascular endothelium with
important functions regarding blood-brain barrier stabi-
lity [35]. This is supported by the fact that reduced
levels of Ang-1 after cerebral ischemia are associated
with blood-brain barrier breakdown [36]. The applica-
tion of COMP-Ang-1, a soluble Ang-1 variant, in rats
Figure 3 Time course of angiopoeitin-1 (Ang-1, ng/ml) in patients with Doppler sonographic cerebral vasospasm (dCVS) compared to
patients without dCVS. Mean and SEM. Data of SAH patients modeled by generalized estimation equations with day post SAH and presence
of dCVS as factors. **, p < 0.01.
Figure 4 Time course of angiopoietin-1 (Ang-1, ng/ml) in patients with cerebral ischemia attributable to vasospasm (CIV) compared to
patients without CIV. Mean and SEM. Data of SAH patients modeled by generalized estimation equations with day post SAH and presence of
CIV as factors. **, p < 0.01.
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deficits [37]. Zhao and colleagues report a protective
effect of Ang-1 in a rat model of cerebral ischemia [36].
We found decreased levels of Ang-1 in patients with
CIV. This further supports a possible protective role of
Ang-1 in ischemic brain damage. Importantly, Ang-1
levels in patients with dCVS differed starting on day 3,
whereas patients with CIV revealed different Ang-1
levels from the very first day. Pathologic alterations,
such as acute CVS, cytotoxic edema and metabolic
changes, have been described immediately after experi-
mental and clinical SAH [38]. The current findings
further corroborate the idea that mechanisms triggered
by the initial bleeding are determining the predisposition
for delayed cerebral infarction. Difference in baseline
Ang-1 might reflect early impairment of vascular func-
tion in those patients, who develop symptomatic vasos-
pasm later on. Surprisingly, we found significant
alterations of Ang-1 associated with dCVS but not with
Ang-2. Ang-1 is a product of pericytes, smooth muscle
cells and fibroblasts, in contrast to Ang-2, which is
mainly expressed by endothelial cells [9,10]. This might
suggest a predominant role of perivascular cell types in
the pathogenesis of CVS. However, further studies are
required to evaluate the preponderance of endothelial or
smooth muscle cell derived mechanisms respectively in
the pathophysiology of cerebral vasospasm during SAH.
I ts h o u l db en o t e dt h a ti nt h ec u r r e n ts t u d yt h ed i a g -
nosis of CVS was based on TCD evaluations and not on
digital subtraction angiography. Although the observed
incidence of dCVS was within the known ranges [6] we
might have missed some patients with CVS since the
sensitivity of TCD in detecting angiographic CVS in not
100% [39,40]. However, analyzing patients with cerebral
ischemia also revealed a significant change in the time
course of Ang-1 serum concentration indicating that
Ang-1 alterations occur in both dCVS and CIV. Though
not necessarily associated with clinical symptoms/neuro-
logic deficits, transient changes in cerebral vasculature,
i.e. dCVS, seem to alter the release of Ang-1 from peri-
vascular cells.
Our study was designed as a pilot study and therefore
only included a small number of patients, which might
be regarded as a limiting factor. Importantly, patients
were well matched and showed a representative distri-
bution of demographic and clinical characteristics. In
addition the incidence of CVS, DCI and mortality was
similar to previously local and international published
data [6,41,42].
Conclusions
In summary, this is the first report of the temporal
dynamics of Ang-1 and Ang-2 during the course of
spontaneous subarachnoid hemorrhage. Ang-1 levels
showed an initial decrease after ictus and a delayed
return to baseline values in patients who developed
dCVS in the course of the disease. In patients suffering
from CIV, lower values of Ang-1 have already been
observed on the day of admission. Ang-1 is likely to
play an important role in SAH pathophysiology and in
the development of CVS. Its exact function in this
regard as well as potential therapeutic implications war-
rant further investigation.
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